Mylan CEO Heather Bresch. Source: Forbes
Shares of Mylan (MYL) to were under pressure last week after news surfaced that patients and pharmacists were struggling to get their hands on the company's emergency allergic reaction treatment, Epipen:
A persistent shortage of Mylan NV's EpiPen anti-allergy injectors is forcing patients and pharmacists to go to great lengths to get their hands on the lifesaving device.
EpiPens, which can help stop a severe or life-threatening allergic reaction, have been hard to get since at least May 2018, when the Food and Drug Administration said the